David Lally, MD describes the hallmark features of geographic atrophy and how the disease develops over time.

Veeral Sheth, MD, MBA describes the presentation of geographic atrophy in patients and how they are first affected by the disease.

David Lally, MD, discusses biomarkers for the progression of geographic atrophy and the lack of previous treatment options for the disease.

Veeral Sheth, MD discusses the two newly FDA-approved therapies for geographic atrophy: pegcetacoplan injection (SYFOVRE) and avacincaptad pegol (IZERVAY).

David Lally, MD describes the association of the complement system with geographic atrophy and how the 2 FDA-approved therapies for GA work to block the complement system.

Veeral Sheth, MD, MBA, discusses the clinical trial data that led to FDA approval of SYFOVRE and IZERVAY for geographic atrophy.

Veeral Sheth, MD, MBA, discusses how clinicians are beginning to use these therapies and the patient reaction to the availability of treatments for GA.

David Lally, MD describes individual phenotypic features in geographic atrophy and determining patient response to treatment.

Veeral Sheth, MD, MBA discusses safety signals reported with the use of approved therapies for geographic atrophy and the importance of real-world datasets.

David Lally, MD highlights safety signals observed with GA therapies in clinical trials and the future of the treatment landscape.

Veeral Sheth, MD, MBA discusses the 3 improvements needed for the future of treating patients with geographic atrophy.